Michael J. Weickert, PhD

Chief Operating Officer

Dr. Weickert has over 26 years of experience in public companies and startups, as an executive and drug developer. Dr. Weickert is CEO of Pacylex and illumiSonics, and was CEO of Sonescence and SEA Medical Systems, CBO of Strategent Life Sciences, Corium, and Therashock, VP of development at SciDose and Auspex, and Senior Program Executive or Manager at Nektar and Ligand. Key roles included raising capital, establishing and maintaining business partnerships, building teams, and developing new products. Michael has driven oncology product development including during the Phase III/NDA for Targretin, and business planning for drug delivery of Leuprolide, Paclitaxel and Irinotecan. He obtained Orphan Drug and Fast Track designations for products in US and EU. He received his PhD from the University of Wisconsin and completed a postdoctoral fellowship at the National Cancer Institute at NIH. He holds 7 issued and 19 pending patents and has 24 publications.

About Us

Ohm Oncology has been established by drug development professionals with years of experience in the ‘bench to bed-side journey’ of a drug. Particularly, the team specializes in oncology and neoplasms with a vision to bring forth novel drugs for the management of treatment-refractory and difficult to treat cancers.

Where we are

2405 Robert Browning St.

Austin, TX 78723

P : +1-408-218-9330

Message us

info@ohmonco.com

Copyrights © 2019 Ohm Oncology
All Rights Reserved